Covant Therapeutics Debuts with Boehringer Partnership Targeting ADAR1

(March 29, 2023) | By Ana Mulero.

Boston-based Covant Therapeutics gained $10 million upfront in a deal with Boehringer Ingelheim to chase after a cancer immunotherapy target, ADAR1 (adenosine deaminase acting on RNA). The goal is to turn cold tumors hot.